Medical Incubator Japan (“MIJ”), an independent venture capital fund investing in early-stage life sciences companies, is pleased to report that since the launch of its second fund in the third quarter of 2020 it has completed two landmark investments in the UK. MIJ’s first investment was in ILC Therapeutics, who are developing treatments for immune diseases, cancer and other viral diseases such as COVID-19 through their work with synthetic interferons. This funding round completed in November 2020 and was followed by MIJ’s investment in Blueberry Therapeutics, a dermatology drug discovery and development company focused on innovative nanomedicines for difficult to treat diseases of the skin and nail. MIJ invested in Blueberry’s Series B extension which completed in January 2021.
MIJ invests across a broad range of innovations including drug discovery, digital health and medical devices. In partnership with Bamburgh Capital, MIJ is particularly focused on...